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Uterine serous papillary cancer (USPC) represents a rare but highly aggressive variant of endometrial cancer, the most common
gynecologic tumour in women. We used oligonucleotide microarrays that interrogate the expression of some 10 000 known genes
to profile 10 highly purified primary USPC cultures and five normal endometrial cells (NEC). We report that unsupervised analysis of
mRNA fingerprints readily distinguished USPC from normal endometrial epithelial cells and identified 139 and 390 genes that
exhibited 45-fold upregulation and downregulation, respectively, in primary USPC when compared to NEC. Many of the genes
upregulated in USPC were found to represent adhesion molecules, secreted proteins and oncogenes, such as
L1 cell adhesion molecule, claudin-3 and claudin-4, kallikrein 6 (protease M) and kallikrein 10 (NES1), interleukin-6 and c-erbB2.
Downregulated genes in USPC included SEMACAP3, ras homolog gene family, member I (ARHI), and differentially downregulated in
ovarian carcinoma gene 1. Quantitative RT–PCR was used to validate differences in gene expression between USPC and NEC for
several of these genes. Owing to its potential as a novel therapeutic marker, expression of the high-affinity epithelial receptor for
Clostridium perfringens enterotoxin (CPE) claudin-4 was further validated through immunohistochemical analysis of formalin-fixed
paraffin-embedded specimens from which the primary USPC cultures were obtained, as well as an independent set of archival USPC
specimens. Finally, the sensitivity of primary USPC to the administration of scalar doses of CPE in vitro was also demonstrated. Our
results highlight the novel molecular features of USPC and provide a foundation for the development of new type-specific therapies
against this highly aggressive variant of endometrial cancer.
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Uterine cancer is the most prevalent gynecologic tumour in
women, with an estimated 40,100 cases and 6800 deaths in the
United States in 2003 (Jemal et al, 2003). On the basis of clinical
and histopathologic variables, two subtypes of endometrial
carcinoma, namely Type I and Type II tumours, have been
described (Bohkman, 1983). Type I endometrial cancers, which
account for the majority (i.e., about 80%) of cases, are usually well
differentiated and endometrioid in histology. These neoplasms are
frequently diagnosed in younger women, are associated with a
history of hyperestrogenism as the main risk factor, and typically
have a favourable prognosis with appropriate therapy. Type II
endometrial cancers are poorly differentiated tumours, often with
serous papillary or clear cell histology, and are not associated with
hyperestrogenic factors. Although Type II tumours account for
only a minority of endometrial carcinoma, about 50% of all
relapses occur in this group of patients.
High-throughput technologies for assaying gene expression,
such as high-density oligonucleotide and cDNA microarrays, have
recently been used in an attempt to define the genetic fingerprints
of a variety of human tumours including endometrial cancers
(Smid-Koopman et al, 2000; Matsushima-Nishiu et al, 2001;
Moreno-Bueno et al, 2003; Risinger et al, 2003). These techniques
may allow precise and accurate grouping of human tumours and
have the potential to identify patients who are unlikely to be cured
by conventional therapy (Sorlie et al, 2001; Rosenwald et al, 2002;
Moreno-Bueno et al, 2003; Risinger et al, 2003). Consistent with
this view, clinically relevant genes highly differentially expressed
between Type I and Type II endometrial tumours have recently
been identified (Moreno-Bueno et al, 2003; Risinger et al, 2003).
Most of the differentially expressed genes in Type I tumours
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included genes known to be hormonally regulated during the
menstrual cycle and known to be important in endometrial
homeostasis (i.e., MGB2, LTF, END1, and MMP11) (Moreno-Bueno
et al, 2003; Risinger et al, 2003). In contrast, Type II tumours have
been shown to overexpress genes involved in the regulation of the
mitotic spindle checkpoint and associated with aneuploidy and an
aggressive phenotype, such as STK15, BUB1, and CCNB2 (Moreno-
Bueno et al, 2003; Risinger et al, 2003).
Uterine serous papillary tumors (USPC) represent the most
aggressive variant of Type II endometrial cancer and may
constitute up to 10% of endometrial tumours. The microscopic
criteria for diagnosis of USPC were first outlined by Hendrickson
et al (1982). Pleomorphism, grade III nuclear atypia with
prominent nucleoli and vesicular chromatin pattern, as well as a
high mitotic activity are commonly detected in this tumour.
Clinically, USPC has a propensity for early intra-abdominal and
lymphatic spread even at presentation and is characterised by a
highly aggressive biologic behaviour (Hendrickson et al, 1982;
Nicklin and Copeland, 1996). Unlike the histologically indis-
tinguishable high-grade serous ovarian carcinomas, USPC is a
chemoresistant disease from onset, with responses to combined
cisplatinum-based chemotherapy in the order of 20% and of short
duration (Nicklin and Copeland, 1996). The overall 5-year survival
is about 30% for all stages and the recurrence rate after surgery is
extremely high (50–80%). A deeper understanding of the
molecular basis of the aggressive biologic behaviour of USPC as
well as the development of novel, more specific and more effective
treatment modalities against this variant of endometrial cancer
remain a high priority.
In this study, with the goal of identifying genes with a
differential pattern of expression between USPC and normal
endometrial cells (NEC) and to use this knowledge for the
development of novel diagnostic and therapeutic markers against
this disease, we used oligonucleotide microarrays which inter-
rogate the expression of some 10 000 known genes to analyse gene
expression profiling of 10 highly purified primary USPC cultures
and five primary NEC. We report a number of genes which may
readily distinguish USPC from normal endometrial epithelial cells.
More importantly, these results highlight the novel molecular
features of USPC and provide a foundation for the development of
new type-specific diagnostic and therapeutic strategies for this
disease.
MATERIALS AND METHODS
Establishment of USPC and NEC primary cell lines
A total of 15 primary cell lines (i.e., 10 USPC and five NEC) were
established after sterile processing of samples from surgical
biopsies collected between 1997 and 2004 at the University
of Arkansas for Medical Sciences, as previously described for
USPC specimens (Santin et al, 2002) and NEC cultures (Bongso
et al, 1988). All fresh samples were obtained with appropriate
consent according to IRB guidelines. Tumours were staged
according to the FIGO operative staging system. A total abdominal
hysterectomy with bilateral salpingo oophorectomy and bilateral
pelvic lymphadenectomy was performed in all uterine carcinoma
patients, while normal endometrial tissue was obtained from
consenting donors undergoing surgery for benign pathology.
No patient received chemotherapy or radiation before surgery.
The patient characteristics are described in Table 1. Tumour
cells were collected for RNA extraction at a confluence of 50– 80%
after a minimum of two to a maximum of 10 passages in vitro.
The epithelial nature and the purity of USPC and NEC cultures
were verified by immunohistochemical staining and flow-
cytometric analysis with antibodies against cytokeratin and
vimentin as described previously (Bongso et al, 1988; Santin
et al, 2002). Only primary cultures which had at least 90% viability
and contained 499% epithelial cells were used for total RNA
extraction.
RNA purification and microarray hybridization and
analysis
Detailed protocols for RNA purification, cDNA synthesis, cRNA
preparation, and hybridization to the Affymetrix Human U95Av2
GeneChip microarray were performed according to the manufac-
turer’s protocols, as reported previously (Zhan et al, 2002).
Data processing
All data used in our analyses were derived from Affymetrix 5.0
software. GeneChip 5.0 output files are given as a signal that
represents the difference between the intensities of the sequence-
specific perfect match probe set and the mismatch probe set, or as
a detection of present, marginal, or absent signals as determined
by the GeneChip 5.0 algorithm. Gene arrays were scaled to an
average signal of 1500 and then analysed independently. Signal
calls were transformed by the log base 2 and each sample was
normalized to give a mean of 0 and variance of 1.
Gene expression data analysis
Statistical analyses of the data were performed with the software
packages SPSS10.0 (SPSS, Chicago, IL) and the significance
analysis of microarrays (SAM) method (Tusher et al, 2001). Genes
were selected for analysis based on detection and fold change. In
each comparison, genes having ‘present’ detection calls in more
than half of the samples in the overexpressed gene group were
retained for statistical analysis if they showed 45-fold change
between groups. Retained genes were subjected to SAM to
establish a false discovery rate (FDR), then further filtered via
the Wilcoxon rank sum (WRS) test at alpha¼ 0.05. The FDR
obtained from the initial SAM analysis was assumed to characterise
genes found significant via WRS.
Gene cluster/treeview
The hierarchical clustering of average-linkage method with the
centred correlation metric was used (Eisen et al, 1998). For the
unsupervised hierarchical clustering, a total of 7328 probe sets
were scanned across 10 USPCs and five NECs. The 7328 probe sets
were derived from 12 588 by filtering out all control genes, all genes
with absent detections, and genes not fulfilling the test of standard
deviation greater than 0.5 (0.5 being the log base 2 of the signal).
Only genes significantly expressed by both WRS and SAM analyses
and whose average change in expression level was at least five-fold
are shown in the Results section.
Table 1 Characteristics of the patients
Patient Age Race Stage
USPC 1 65 White IV B
USPC 2 75 Afro-American III C
USPC 3 75 Afro-American IV A
USPC 4 59 White IV A
USPC 5 59 White III C
USPC 6 62 Afro-American IV B
USPC 7 63 Afro-American III C
USPC 8 61 Afro-American III C
USPC 9 78 White III C
USPC 10 64 Afro-American IV A
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Quantitative real-time PCR (q-RT–PCR)
Quantitative real-time PCR was performed with an ABI Prism 7000
Sequence Analyzer using the manufacturer’s recommended pro-
tocol (Applied Biosystems, Foster City, CA, USA) to validate
differential expression of selected genes in samples from all 15
primary cell lines (10 USPC and five NEC). Each reaction was run
in triplicate. The comparative threshold cycle (CT) method was
used for the calculation of amplification fold as specified by the
manufacturer. Briefly, 5 mg of total RNA from each sample was
reverse transcribed using SuperScript II Rnase H Reverse
Transcriptase (Invitrogen, Carlsbad, CA, USA). In all, 10 ml of
reverse-transcribed RNA samples (from 500 ml of total volume)
was amplified by using the TaqMan Universal PCR Master Mix
(Applied Biosystems) to produce PCR products specific for cyclin-
dependent kinase inhibitor 2A (CDKN2A/p16 and CDKN2A/
p14ARF), L1 cell adhesion molecule (L1CAM), claudin-3, claudin-
4, GRB7, and c-erbB2. Primers specific for 18s ribosomal RNA and
empirically determined ratios of 18s competimers (Applied
Biosystems) were used to control for the amounts of cDNA
generated from each sample. Sequences for primers and probes are
available on request. Differences among USPC and NEC in the
q-RT– PCR expression data were tested using the Kruskal– Wallis
nonparametric test. Pearson product –moment correlations were
used to estimate the degree of association between the microarray
and q-RT– PCR data.
Claudin-4 immunostaining of formalin-fixed tumour
tissues
Claudin-4 protein expression was evaluated by immunohisto-
chemical staining on formalin-fixed tumour tissue from which
primary cultures were obtained. In addition, to further confirm
transcriptional profiling results of USPC, claudin-4 marker was
also evaluated by immunohistochemistry in a second independent
set of eight USPC clinical tissue samples obtained from patients
harbouring advanced stage disease (i.e., stage III and IV) treated at
the UAMS during the same period. Study blocks were selected after
histopathologic review by a surgical pathologist. The most
representative haematoxylin and eosin-stained block sections were
used for each specimen. Briefly, immunohistochemical stains were
performed on 4-mm-thick sections of formalin-fixed, paraffin-
embedded tissue. After pretreatment with 10 mM citrate buffer at
pH 6.0 using a steamer, they were incubated with mouse anti-
claudin-4 antibodies (cat. #: 18-7341; Zymed Laboratories Inc.,
San Francisco, CA, USA) at 1 : 2000 dilution. Antigen-bound
primary antibodies were detected using standard avidin–biotin
immunoperoxidase complex (Dako Corp., Carpinteria, CA, USA).
Cases with less than 10% staining in tumour cells were considered
negative for claudin expression, while positive cases were classified
as follows regarding the intensity of claudin-4 protein expression:
(a) þ , focal membrane staining; (b) þ þ , diffuse membrane
staining; and (c) þ þ þ , diffuse membrane and cytoplasmic
staining.
Clostridium perfringens enterotoxin (CPE) treatment of
primary USPC cell lines and trypan blue exclusion test
Tumour samples obtained from three patients harbouring
advanced USPC (i.e., USPC 1, USPC 2, and USPC 3) and two
NEC cultures derived from similar-aged women were seeded at a
concentration of 1 105 cells well1 into six-well culture plates
(Costar, Cambridge, MA, USA) with the appropriate medium.
Tumour samples and control cell lines were grown to 80%
confluence. After washing and renewal of the medium, recombi-
nant CPE cloned and purified as previously described (Michl et al,
2001) was added to final concentrations ranging from 0.03 to
3.3mg ml1. After incubation for 60 min to 24 h at 371C, 5% CO2,
floating cells were removed and stored, and attached cells were
trypsinised and pooled with the floating cells. After staining with
trypan blue, viability was determined by counting the number of
trypan blue-positive cells and the total cell number.
RESULTS
Gene expression profiles distinguish USPC from NEC and
identify differentially expressed genes
To minimise the risk of contamination of USPC RNA with that
of normal cells or tumour cells with different histology (i.e.,
endometrioid or clear cells), as well as to reduce the complexity of
gene expression data analysis, in this study we extracted RNA from
short-term primary tumour cell cultures collected only from USPC
with single-type differentiation (i.e., pure USPC). Short-term USPC
and NEC cell cultures, minimising the risk of a selection bias
inherent in any long-term in vitro growth, may provide an
opportunity to study differential gene expression between highly
enriched populations of normal and tumour-derived epithelial
cells. Accordingly, comprehensive gene expression profiles of 10
primary USPC and five primary NEC cell lines were generated
using high-density oligonucleotide arrays with 12 588 probe sets,
which in total interrogated some 10 000 genes. Using unsupervised
hierarchical cluster analysis with 7238 probe sets, we identified
differences in gene expression between USPC and NEC, which
readily distinguished the two groups of primary cultures. As
shown in Figure 1, all 10 USPC were found to group together in the
rightmost columns of the dendrogram. Similarly, in the leftmost
columns, all five NEC were found to cluster tightly together. After
filtering out most ‘absent’ genes, the SAM and the nonparametric
WRS test (Po0.05) were performed to identify genes differentially
expressed between USPC and NEC. A total of 2829 probe sets were
found differentially expressed between USPC and NEC with
Po0.05 by WRS and with a median FDR of 0.35% and a 90th
percentile FDR of 0.59% by SAM. Of the 2829 aforementioned
probe sets, there were 529 probe sets showing 45-fold change. As
shown in Table 2, a group of 139 probe sets were found highly
expressed in USPC and underexpressed in NEC. Included in this
group of genes are CDKN2A/p16/p14ARF (101-fold), L1CAM (25-
fold), claudin-3 (eight-fold), and claudin-4 (12-fold), kallikrein 6
NEC5
NEC3
NEC4
NEC2
NEC1
USPC08
USPC07
USPC06
USPC10
USPC09
USPC03
USPC02
USPC04
USPC05
USPC01
Figure 1 Unsupervised hierarchical clustering of 15 primary uterine cell
lines (i.e., 10 USPC and five NEC). The cluster is colour coded using red for
upregulation, green for downregulation, and black for median expression.
Agglomerative clustering of genes is illustrated with dendrograms.
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Table 2 Upregulated genes expressed at least five-fold higher in USPC compared with NEC
Probe set
Gene
symbol SAM
P of
WRS
Ratio USPC/
NEC Title
1713_s_at CDKN2Aa 10.592 0.0027 101.9077377 ‘Cyclin-dependent kinase inhibitor 2A (melanoma, p16)’
36288_at KRTHB1 4.573 0.0027 77.3983986 ‘Keratin, hair, basic, 1’
33272_at SAA1 3.778 0.0063 45.74937337 Serum amyloid A1
41294_at KRT7 7.173 0.0027 41.46788873 Keratin 7
32154_at TFAP2A 7.637 0.0027 32.47929396 Transcription factor AP-2 alpha
31610_at MAP17 3.621 0.0093 30.28302802 Membrane-associated protein 17
408_at — 4.070 0.0063 30.14111158 —
32821_at LCN2 5.126 0.0027 27.69975608 Lipocalin 2 (oncogene 24p3)
35174_i_at EEF1A2 2.840 0.0278 26.80482891 Elongation factor 1 alpha 2
38551_at L1CAM 3.115 0.0196 25.60938089 ‘L1 cell adhesion molecule
38249_at VGLL1 5.274 0.0027 24.69495091 Vestigial like 1 (Drosophila)
35879_at GAL 5.594 0.0027 23.48953559 Galanin
36838_at KLK10 3.455 0.0136 23.17518549 Kallikrein 10
38299_at IL6 3.630 0.0041 19.05873079 ‘Interleukin 6 (interferon, beta 2)’
38051_at MAL 4.878 0.0041 17.51555106 ‘mal, T-cell differentiation protein’
41469_at PI3 2.854 0.0063 16.90464558 ‘Protease inhibitor 3, skin-derived (SKALP)’
40412_at PTTG1 5.218 0.0027 16.61222352 Pituitary tumour-transforming 1
1886_at WNT7A 3.544 0.0196 16.11519778 ‘Wingless-type MMTV integration site family, member 7A’
33128_s_at CST6 4.222 0.0136 15.97856318 Cystatin E/M
38414_at CDC20 7.317 0.0027 15.64601435 CDC20 cell division cycle 20 homolog (S. cerevisiae)
34012_at KRTHA4 2.411 0.0278 15.37247475 ‘Keratin, hair, acidic, 4’
37554_at KLK6 3.785 0.0093 15.23781352 ‘Kallikrein 6 (neurosin, zyme)’
1802_s_at ERBB2 2.566 0.0136 14.52012028 ‘v-erb-b2’
41060_at CCNE1 6.092 0.0027 14.16647068 Cyclin E1
36837_at KIF2C 6.130 0.0027 14.1328483 Kinesin family member 2C
34213_at KIBRA 5.301 0.0027 13.27228177 KIBRA protein
1651_at UBE2C 5.554 0.0027 12.87617243 Ubiquitin-conjugating enzyme E2C
35276_at CLDN4 6.381 0.0027 12.74825421 Claudin 4
36990_at UCHL1 4.623 0.0027 12.30505908 Ubiquitin carboxyl-terminal esterase L1
35977_at DKK1 4.495 0.0041 12.25382636 Dickkopf homolog 1 (Xenopus laevis)
36113_s_at TNNT1 4.072 0.0027 11.93824813 ‘Troponin T1, skeletal, slow’
2011_s_at BIK 3.451 0.0063 11.66959681 BCL2-interacting killer (apoptosis-inducing)
543_g_at CRABP1 3.193 0.0093 11.55494382 Cellular retinoic acid binding protein 1
34852_g_at STK6 6.225 0.0027 11.51812047 Serine/threonine kinase 6
33483_at NMU 4.094 0.0027 11.42057993 Neuromedin U
39109_at TPX2 6.162 0.0027 11.29208457 ‘TPX2, microtubule-associated protein homologue’
37018_at HIST1H1C 2.270 0.0278 10.74270622 ‘Histone 1, H1c’
1165_at IL18 3.221 0.0041 10.65596528 Interleukin 18 (interferon-gamma-inducing factor)
36477_at TNNI3 2.867 0.0136 10.61101382 ‘Troponin I, cardiac’
572_at TTK 3.720 0.0093 9.723902052 TTK protein kinase
31542_at FLG 2.622 0.0196 9.600831601 Filaggrin
35937_at MICB 4.238 0.0093 9.460109582 MHC class I polypeptide-related sequence B
36155_at SPOCK2 2.278 0.0278 9.216570003 ‘Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2’
32186_at SLC7A5 4.149 0.0063 9.121679665 ‘Solute carrier family 7 (cationic amino-acid transporter, y+ system), member 5’
35766_at KRT18 5.933 0.0027 9.01220054 Keratin 18
35822_at BF 3.267 0.0063 8.952514469 ‘B-factor, properdin’
35714_at PDXK 6.550 0.0027 8.898191704 ‘Pyridoxal (pyridoxine, vitamin B6) kinase’
1369_s_at — 2.679 0.0196 8.773380878 —
40079_at RAI3 4.516 0.0063 8.626843209 Retinoic acid induced 3
37168_at LAMP3 2.838 0.0136 8.616807346 Lysosomal-associated membrane protein 3
39704_s_at HMGA1 5.322 0.0027 8.597894471 High-mobility group AT-hook 1
1887_g_at WNT7A 3.003 0.0196 8.491813649 ‘Wingless-type MMTV integration site family, member 7A’
36929_at LAMB3 5.770 0.0027 8.354149098 ‘Laminin, beta 3’
527_at CENPA 6.126 0.0027 8.32992789 ‘Centromere protein A, 17 kDa’
41081_at BUB1 4.883 0.0027 8.213759056 BUB1 budding uninhibited by benzimidazoles 1 homologue
885_g_at ITGA3 4.447 0.0027 8.20660555 ‘Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)’
2021_s_at CCNE1 4.399 0.0041 8.199388463 Cyclin E1
33904_at CLDN3 3.296 0.0136 8.020010794 Claudin 3
33730_at RAI3 4.648 0.0041 7.923899439 Retinoic acid induced 3
34736_at CCNB1 5.078 0.0063 7.896644626 Cyclin B1
757_at ANXA2 3.514 0.0063 7.870466864 Annexin A2
910_at TK1 3.934 0.0093 7.869091533 ‘Thymidine kinase 1, soluble’
34851_at STK6 4.491 0.0041 7.764803777 Serine/threonine kinase 6
34703_f_at — 2.275 0.0278 7.710260816 —
34715_at FOXM1 5.318 0.0027 7.659023602 Forkhead box M1
38971_r_at TNIP1 6.800 0.0027 7.595036872 TNFAIP3 interacting protein 1
32263_at CCNB2 4.246 0.0063 7.578513543 Cyclin B2
1680_at GRB7 4.013 0.0027 7.471384928 Growth factor receptor-bound protein 7
38247_at F2RL1 3.185 0.0093 7.432476326 Coagulation factor II (thrombin) receptor-like 1
160025_at TGFA 6.088 0.0027 7.355344272 ‘Transforming growth factor, alpha’
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Table 2 (Continued )
Probe set
Gene
symbol SAM
P of
WRS
Ratio USPC/
NEC Title
1945_at CCNB1 5.298 0.0041 7.291039832 Cyclin B1
31792_at ANXA3 4.873 0.0041 7.266892828 Annexin A3
182_at ITPR3 5.432 0.0027 7.172450367 ‘Inositol 1,4,5-triphosphate receptor, type 3’
1117_at CDA 2.937 0.0093 7.114518646 Cytidine deaminase
902_at EPHB2 5.186 0.0027 7.065363569 EphB2
634_at PRSS8 5.216 0.0041 7.001894703 ‘Protease, serine, 8 (prostasin)’
41169_at PLAUR 3.982 0.0063 7.00139089 ‘Plasminogen activator, urokinase receptor’
33203_s_at FOXD1 3.464 0.0093 6.989749222 Forkhead box D1
40095_at CA2 4.285 0.0027 6.946396937 Carbonic anhydrase II
38940_at AD024 5.065 0.0041 6.928406028 AD024 protein
34348_at SPINT2 6.263 0.0027 6.877224695 ‘Serine protease inhibitor, Kunitz type, 2’
33933_at WFDC2 3.344 0.0136 6.820073691 WAP four-disulphide core domain 2
35281_at LAMC2 3.347 0.0093 6.7580474 ‘Laminin, gamma 2’
349_g_at KIFC1 5.275 0.0041 6.700913018 Kinesin family member C1
33218_at ERBB2 2.710 0.0027 6.615105998 ‘v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene
homolog (avian)’
38881_i_at TRIM16 3.001 0.0196 6.506893575 Tripartite motif-containing 16
1536_at CDC6 4.666 0.0041 6.463305623 CDC6 cell division cycle 6 homolog (S. cerevisiae)
38482_at CLDN7 4.931 0.0041 6.409117877 Claudin 7
40697_at CCNA2 3.396 0.0093 6.40768505 Cyclin A2
41688_at TM4SF11 4.390 0.0027 6.366861533 Transmembrane 4 superfamily member 11 (plasmolipin)
38158_at ESPL1 6.007 0.0027 6.225688779 Extra spindle poles like 1 (S. cerevisiae)
38474_at CBS 3.380 0.0093 6.212078913 Cystathionine-beta-synthase
36483_at GALNT3 3.890 0.0041 6.181109111 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 3 (GalNAc-T3)
35372_r_at IL8 2.360 0.0278 6.133149591 Interleukin 8
41585_at KIAA0746 4.436 0.0027 6.092207586 KIAA0746 protein
36832_at B3GNT3 5.457 0.0027 5.941291793 ‘UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3’
1107_s_at G1P2 3.938 0.0063 5.923287019 ‘Interferon, alpha-inducible protein (clone IFI-15K)’
35207_at SCNN1A 3.076 0.0136 5.920739634 ‘Sodium channel, nonvoltage-gated 1 alpha’
36863_at HMMR 2.830 0.0196 5.905038013 Hyaluronan-mediated motility receptor (RHAMM)
38631_at TNFAIP2 4.924 0.0027 5.897745642 ‘Tumour necrosis factor, alpha-induced protein 2’
36813_at TRIP13 5.666 0.0027 5.870351247 Thyroid hormone receptor interactor 13
41048_at PMAIP1 3.490 0.0062 5.853172336 Phorbol-12-myristate-13-acetate-induced protein 1
2084_s_at ETV4 3.743 0.0093 5.798002338 ‘ets variant gene 4 (E1A enhancer binding protein, E1AF)’
33245_at MAPK13 3.775 0.0136 5.766618762 Mitogen-activated protein kinase 13
37347_at CKS1B 5.543 0.0027 5.762817533 CDC28 protein kinase regulatory subunit 1B
34282_at NFE2L3 2.668 0.0136 5.734907375 Nuclear factor (erythroid-derived 2)-like 3
330_s_at — 4.026 0.0041 5.726752495 —
41732_at na 6.920 0.0027 5.706487141 Similar to My016 protein
1516_g_at — 6.726 0.0027 5.63870137 —
904_s_at TOP2A 3.419 0.0063 5.634251452 Topoisomerase (DNA) II alpha 170 kDa
36041_at EXO1 4.971 0.0027 5.59235892 Exonuclease 1
33143_s_at SLC16A3 4.007 0.0063 5.56591457 ‘Solute carrier family 16 (monocarboxylic acid transporters), member 3’
37228_at PLK 4.501 0.0041 5.564532365 Polo-like kinase (Drosophila)
1854_at MYBL2 4.117 0.0063 5.54317592 v-myb myeloblastosis viral oncogene homolog (avian)-like 2
40407_at KPNA2 4.189 0.0041 5.51635645 ‘Karyopherin alpha 2 (RAG cohort 1, importin alpha 1)’
33282_at LAD1 3.904 0.0063 5.509367036 Ladinin 1
40145_at TOP2A 3.307 0.0093 5.48127065 Topoisomerase (DNA) II alpha 170 kDa
1100_at IRAK1 5.530 0.0027 5.470162749 Interleukin-1 receptor-associated kinase 1
37883_i_at AF038169 3.160 0.0027 5.460495655 Hypothetical protein AF038169
37343_at ITPR3 5.258 0.0027 5.449013729 ‘Inositol 1,4,5-triphosphate receptor, type 3’
31598_s_at GALE 4.647 0.0027 5.442955253 ‘Galactose-4-epimerase, UDP-’
889_at ITGB8 2.744 0.0093 5.370592815 ‘Integrin, beta 8’
37558_at IMP-3 3.123 0.0093 5.364127468 IGF-II mRNA-binding protein 3
32715_at VAMP8 5.686 0.0027 5.352873419 Vesicle-associated membrane protein 8 (endobrevin)
36312_at SERPINB8 3.611 0.0027 5.327343554 ‘Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 8’
37210_at INA 3.551 0.0063 5.307526088 ‘Internexin neuronal intermediate filament protein, alpha’
35699_at BUB1B 3.665 0.0196 5.279075308 BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast)
32787_at ERBB3 2.658 0.0041 5.247404657 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)
32275_at SLPI 3.726 0.0041 5.221163981 Secretory leukocyte protease inhibitor (antileukoproteinase)
893_at E2-EPF 3.775 0.0063 5.196412396 Ubiquitin carrier protein
41583_at FEN1 5.481 0.0027 5.196005796 Flap structure-specific endonuclease 1
41781_at PPFIA1 4.113 0.0027 5.194931774 ‘Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1’
40726_at KIF11 2.941 0.0093 5.1806793 Kinesin family member 11
41400_at TK1 4.246 0.0093 5.167172588 ‘Thymidine kinase 1, soluble’
41409_at C1orf38 3.109 0.0063 5.100239097 Chromosome 1 open reading frame 38
40425_at EFNA1 2.738 0.0196 5.067718102 Ephrin-A1
32081_at CIT 6.162 0.0027 5.043567722 ‘Citron (rho-interacting, serine/threonine kinase 21)’
1108_s_at EPHA1 4.864 0.0027 5.040980858 EphA1
33338_at STAT1 3.275 0.0063 5.029498048 ‘Signal transducer and activator of transcription 1, 91 kDa’
aGenes selected for further analysis are identified with bold letters.
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Table 3 Upregulated genes expressed at least 10-fold higher in NEC compared with USPC
Probe set Gene symbol SAM P of WRS Ratio NEC/USPC Title
774_g_at MYH11 17.611 0.0027 1014.968759 ‘Myosin, heavy polypeptide 11, smooth muscle’
773_at MYH11 14.265 0.0027 968.0223497 ‘Myosin, heavy polypeptide 11, smooth muscle’
32582_at MYH11 11.277 0.0027 212.2458648 ‘Myosin, heavy polypeptide 11, smooth muscle’
36681_at APOD 11.714 0.0027 137.3140116 Apolipoprotein D
1501_at IGF1 8.321 0.0027 128.0651104 Insulin-like growth factor 1 (somatomedin C)
39325_at EBAF 8.177 0.0027 123.064609 ‘Endometrial bleeding associated factor)’
767_at — 12.707 0.0027 119.5409103 —
40398_s_at MEOX2 10.182 0.0027 114.9489897 Mesenchyme homeo box 2
40776_at DES 9.738 0.0027 109.416397 Desmin
1197_at ACTG2 5.861 0.0027 96.65715109 ‘Actin, gamma 2, smooth muscle, enteric’
36627_at SPARCL1 7.724 0.0027 93.89302842 ‘SPARC-like 1 (mast9, hevin)’
37407_s_at MYH11 11.893 0.0027 88.70362054 ‘Myosin, heavy polypeptide 11, smooth muscle’
39673_i_at ECM2 8.459 0.0027 82.52353674 ‘Extracellular matrix protein 2, female organ and adipocyte specific’
39701_at PEG3 7.645 0.0027 73.87997223 Paternally expressed gene 3
39066_at MFAP4 9.383 0.0027 68.84723295 Microfibrillar-associated protein 4
38737_at IGF1 6.341 0.0027 65.13666715 Insulin-like growth factor 1 (somatomedin C)
35730_at ADH1B 9.759 0.0027 64.94146631 ‘Alcohol dehydrogenase IB (class I), beta polypeptide’
41124_r_at ENPP2 7.007 0.0027 53.43118221 Ectonucleotide pyrophosphatase/phosphodiesterase 2 (autotaxin)
36749_at CPA3 9.096 0.0027 53.07347991 Carboxypeptidase A3 (mast cell)
39616_at PTGER3 10.188 0.0027 52.65326101 Prostaglandin E receptor 3 (subtype EP3)
33440_at TCF8 7.220 0.0027 49.54168001 Transcription factor 8
32666_at CXCL12 7.168 0.0027 49.2359637 Chemokine (C–X–C motif) ligand 12
38734_at PLN 9.182 0.0027 47.86730799 Phospholamban
34203_at CNN1 5.051 0.0027 47.0209722 ‘Calponin 1, basic, smooth muscle’
37576_at PCP4 12.468 0.0027 45.45542357 Purkinje cell protein 4
36834_at MOXD1 9.736 0.0027 44.20917891 ‘Monooxygenase, DBH-like 1’
37247_at TCF21 9.810 0.0027 42.40051895 Transcription factor 21
37701_at RGS2 7.408 0.0027 42.29038464 ‘Regulator of G-protein signalling 2, 24 kDa’
779_at COL4A6 5.840 0.0027 41.96325597 ‘Collagen, type IV, alpha 6’
37394_at C7 9.835 0.0027 40.72326307 Complement component 7
36533_at PTGIS 6.097 0.0027 39.10052985 Prostaglandin I2 (prostacyclin) synthase
32689_s_at — 6.178 0.0027 36.96897988 —
32905_s_at TPSB2 6.873 0.0027 36.85974711 Tryptase beta 2
33240_at SEMACAP3 4.814 0.0027 36.54583796 Likely ortholog of mouse semaF cytoplasmic domain associated protein 3
1466_s_at FGF7 8.628 0.0027 35.60413415 Fibroblast growth factor 7
32686_at PTGER3 7.397 0.0027 35.31357002 Prostaglandin E receptor 3 (subtype EP3)
39690_at ALP 6.951 0.0027 33.76045029 Alpha-actinin-2-associated LIM protein
38427_at COL15A1 7.196 0.0027 32.85391153 ‘Collagen, type XV, alpha 1’
39939_at COL4A6 6.846 0.0027 32.53815505 ‘Collagen, type IV, alpha 6’
37630_at NRLN1 5.896 0.0027 31.03030255 Neuralin 1
35717_at ABCA8 7.587 0.0027 30.63819827 ‘ATP-binding cassette, subfamily A, member 8’
1709_g_at MAPK10 6.522 0.0027 30.54331363 Mitogen-activated protein kinase 10
35679_s_at DPP6 5.899 0.0027 30.33959319 Dipeptidylpeptidase 6
35740_at EMILIN1 7.445 0.0027 29.45261895 Elastin microfibril interfacer 1
41123_s_at ENPP2 6.597 0.0027 29.29614059 Ectonucleotide pyrophosphatase/phosphodiesterase 2 (autotaxin)
755_at ITPR1 8.211 0.0027 29.02124207 ‘Inositol 1,4,5-triphosphate receptor, type 1’
32847_at MYLK 5.388 0.0027 28.22518538 ‘Myosin, light polypeptide kinase’
38001_at CACNA1C 5.740 0.0027 27.31347302 ‘Calcium channel, alpha 1C subunit’
37279_at GEM 9.925 0.0027 26.56613192 GTP-binding protein overexpressed in skeletal muscle
36396_at — 5.901 0.0027 26.32457357 Homo sapiens mRNA; cDNA DKFZp586N2020 (from clone DKFZp586N2020)
41137_at PPP1R12B 12.043 0.0027 25.97089935 ‘Protein phosphatase 1, regulatory subunit 12B’
41405_at SFRP4 10.077 0.0027 23.90433923 Secreted frizzled-related protein 4
40775_at ITM2A 6.152 0.0027 23.83083993 Integral membrane protein 2A
38059_g_at DPT 6.508 0.0027 23.76376781 Dermatopontin
41504_s_at MAF 5.331 0.0027 23.65323618 v-maf
1596_g_at TEK 4.542 0.0027 23.37422615 ‘TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and
mucosal)’
914_g_at ERG 6.105 0.0027 22.63829292 v-ets erythroblastosis virus E26 oncogene like
34283_at — 5.390 0.0041 22.19917455 ‘Homo sapiens, clone IMAGE:4791553, mRNA’
34388_at COL14A1 9.452 0.0027 21.48165459 ‘Collagen, type XIV, alpha 1 (undulin)’
38994_at SOCS2 6.600 0.0027 21.47663968 Suppressor of cytokine signaling 2
36065_at LDB2 5.790 0.0027 21.19321308 LIM domain binding 2
40230_at FRZB 5.962 0.0027 21.00467856 Frizzled-related protein
33790_at CCL15 9.017 0.0027 20.5510028 Chemokine (C–C motif) ligand 15
33890_at RGS5 7.347 0.0027 20.2203337 Regulator of G-protein signalling 5
36513_at MAGP2 4.385 0.0041 20.10734871 Microfibril-associated glycoprotein-2
32526_at JAM3 6.129 0.0027 19.89641568 Junctional adhesion molecule 3
32687_s_at PTGER3 5.902 0.0027 19.7194642 Prostaglandin E receptor 3 (subtype EP3)
35638_at CBFA2T1 10.470 0.0027 19.57233853 ‘Core-binding factor, runt domain, alpha subunit 2; translocated to, 1; cyclin D-
related’
34637_f_at ADH1A 6.291 0.0027 19.20847669 ‘Alcohol dehydrogenase 1A (class I)’
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Table 3 (Continued )
Probe set Gene symbol SAM P of WRS Ratio NEC/USPC Title
34675_at SBLF 5.400 0.0027 19.04463285 Stoned B-like factor
38351_at — 5.899 0.0026 18.69131208 Homo sapiens mRNA; cDNA DKFZp586L0120 (from clone DKFZp586L0120)
1182_at PLCL1 4.047 0.0027 18.50958764 Phospholipase C-like 1
39681_at ZNF145 6.266 0.0027 18.41823634 ‘Zinc-finger protein 145 (Kruppel-like, expressed in promyelocytic leukemia)’
1708_at MAPK10 6.336 0.0027 18.31250756 Mitogen-activated protein kinase 10
37765_at LMOD1 7.586 0.0027 18.11624265 Leiomodin 1 (smooth muscle)
1678_g_at IGFBP5 4.237 0.0041 17.88349387 Insulin-like growth factor binding protein 5
35358_at TENC1 9.243 0.0027 17.68277053 Tensin-like C1 domain-containing phosphatase
33442_at KIAA0367 6.830 0.0027 17.58195512 KIAA0367 protein
37249_at PDE8B 5.035 0.0027 17.25176904 Phosphodiesterase 8B
33834_at CXCL12 7.736 0.0027 17.10893345 Chemokine (C–X–C motif) ligand 12 (stromal cell-derived factor 1)
35324_at SLIT3 5.157 0.0027 17.08441711 Slit homolog 3 (Drosophila)
37015_at ALDH1A1 4.941 0.0027 16.83181709 ‘Aldehyde dehydrogenase 1 family, member A1’
39266_at — 6.237 0.0027 16.80733058 Homo sapiens clone 24405 mRNA sequence
33462_at GPR105 4.907 0.0027 16.49634139 G protein-coupled receptor 105
32488_at COL3A1 3.928 0.0027 16.44993439 ‘Collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant)’
483_g_at CDH13 3.755 0.0027 16.43857351 ‘Cadherin 13, H-cadherin (heart)’
38026_at FBLN1 5.350 0.0027 16.06497318 Fibulin 1
1909_at BCL2 7.356 0.0027 16.01160367 B-cell CLL/lymphoma 2
36245_at HTR2B 4.698 0.0027 15.77119379 5-Hydroxytryptamine (serotonin) receptor 2B
32057_at LRRC17 5.470 0.0027 15.6891271 Leucine-rich repeat containing 17
39544_at DMN 5.361 0.0027 15.66465434 Desmuslin
37112_at C6orf32 4.720 0.0027 15.65975413 Chromosome 6 open reading frame 32
36733_at FLJ32389 4.442 0.0027 15.64273348 Hypothetical protein FLJ32389
1319_at DDR2 5.400 0.0027 15.5817123 ‘Discoidin domain receptor family, member 2’
38057_at DPT 8.479 0.0027 15.51358362 Dermatopontin
40358_at GLI3 6.650 0.0027 15.11249492 GLI-Kruppel family member GLI3 (Greig cephalopolysyndactyly syndrome)
38627_at HLF 4.947 0.0027 14.89249894 Hepatic leukemia factor
1731_at PDGFRA 7.050 0.0027 14.84422948 ‘Platelet-derived growth factor receptor, alpha polypeptide’
31897_at DOC1 4.664 0.0027 14.80084961 Downregulated in ovarian cancer 1
2073_s_at CDH13 5.076 0.0027 14.79118507 ‘Cadherin 13, H-cadherin (heart)’
38577_at — 7.283 0.0027 14.78670234 ‘Clone DT1P1B6 mRNA, CAG repeat region’
38004_at CSPG4 6.072 0.0027 14.40637488 Chondroitin sulphate proteoglycan 4
32109_at FXYD1 7.333 0.0027 14.33463902 Phospholemman
34853_at FLRT2 9.834 0.0027 14.33080432 Fibronectin leucine-rich transmembrane protein 2
38298_at KCNMB1 7.046 0.0027 14.25816751 ‘Potassium large-conductance calcium-activated channel, subfamily M, beta member
1’
41245_at GDF10 6.643 0.0027 14.21467179 Growth differentiation factor 10
38322_at GAGEC1 6.215 0.0027 14.10508119 ‘G antigen, family C, 1’
1198_at EDNRB 4.899 0.0027 14.08196951 Endothelin receptor type B
41505_r_at MAF 4.528 0.0027 14.0059518 v-maf
36976_at CDH11 3.692 0.0027 14.00329993 ‘Cadherin 11, type 2, OB-cadherin (osteoblast)’
32688_at PTGER3 4.998 0.0027 13.68791213 Prostaglandin E receptor 3 (subtype EP3)
1575_at ABCB1 6.210 0.0027 13.64196645 ‘ATP-binding cassette, subfamily B’
32778_at ITPR1 4.914 0.0027 13.60359986 ‘Inositol 1,4,5-triphosphate receptor, type 1’
40737_at KCNMA1 5.642 0.0027 13.60011778 ‘potassium large-conductance calcium-activated channel, subfamily M, alpha
member 1’
36569_at TNA 11.512 0.0027 13.14186685 Tetranectin (plasminogen-binding protein)
1897_at TGFBR3 4.922 0.0041 12.99722509 ‘Transforming growth factor, beta receptor III (betaglycan, 300 kDa)’
2087_s_at CDH11 4.345 0.0027 12.96131894 ‘Cadherin 11, type 2, OB-cadherin (osteoblast)’
34820_at PTN 4.413 0.0041 12.94626537 ‘Pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1)’
743_at NAP1L3 7.859 0.0027 12.91061134 Nucleosome assembly protein 1-like 3
1507_s_at EDNRA 4.319 0.0041 12.88466839 Endothelin receptor type A
38995_at CLDN5 12.156 0.0027 12.86636376 Claudin 5 (transmembrane protein deleted in velocardiofacial syndrome)
1147_at — 7.084 0.0027 12.69931721 —
1954_at KDR 6.077 0.0027 12.6174344 Kinase insert domain receptor (a type III receptor tyrosine kinase)
38786_at — 5.676 0.0027 12.61170471 Homo sapiens mRNA full-length insert cDNA clone EUROIMAGE 248114
40757_at GZMA 4.575 0.0041 12.56281091 ‘Granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3)’
36695_at na 5.776 0.0027 12.53905775 Similar to hypothetical protein 6720478C22
32052_at HBB 5.107 0.0063 12.52262761 ‘Haemoglobin, beta’
37446_at GASP 8.227 0.0027 12.39360585 G protein-coupled receptor-associated protein
38038_at LUM 4.462 0.0027 12.34757673 Lumican
32889_at RPIB9 6.337 0.0027 12.34540513 Rap2-binding protein 9
35234_at RECK 4.476 0.0027 12.33793353 Reversion-inducing-cysteine-rich protein
661_at GAS1 4.648 0.0027 12.32556384 Growth arrest-specific 1
41195_at LPP 6.292 0.0027 12.26636801 LIM domain containing preferred translocation partner in lipoma
32664_at RNASE4 6.395 0.0027 11.89680804 ‘Ribonuclease, RNase A family, 4’
39038_at FBLN5 4.325 0.0027 11.89440528 Fibulin 5
40693_at KCNB1 4.952 0.0041 11.84773944 ‘Potassium voltage-gated channel, Shab-related subfamily, member 1’
38052_at F13A1 5.346 0.0027 11.69181717 ‘Coagulation factor XIII, A1 polypeptide’
35220_at ENPEP 4.200 0.0027 11.66308093 Glutamyl aminopeptidase (aminopeptidase A)
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(protease M) (19-fold), and kallikrein 10 (NES1) (23-fold),
interleukin-6 (19-fold), interleukin-18 (10-fold), and plasminogen
activator receptor (PLAUR) (seven-fold) (Table 2). Importantly,
c-erbB2, a gene recently found by our group to be highly
differentially expressed in USPC when compared to ovarian serous
papillary tumours (Santin et al, 2004), was 14-fold more highly
expressed in USPC than in NEC (Table 2). The second profile was
represented by 390 genes that were highly expressed in NEC and
underexpressed in USPC. Table 3 depicts the genes showing 410-
fold change. Included in this group of genes are transforming
growth factor beta receptor III, platelet-derived growth factor
receptor alpha, SEMACAP3, ras homolog gene family, member I
(ARHI), and differentially downregulated in ovarian carcinoma 1
(DOC1).
Validation of the microarray data
We used q-RT– PCR assays to validate the microarray data. Seven
highly differentially expressed genes between USPC and NEC (i.e.,
CDKN2A/p16, CDKN2A/p14ARF (101-fold), L1CAM (25-fold),
claudin-3 (eight-fold), claudin-4 (12-fold), GRB-7 (19-fold), and
c-erbB2 (14-fold)) were selected for q-RT– PCR analysis. A
comparison of the microarray and q-RT–PCR data for six of
these genes is shown in Figure 2. Expression differences between
USPC and NEC for CDKN2A/p16 (P¼ 0.002), CDKN2A/p14ARF
(P¼ 0.002), claudin-3 (P¼ 0.01), claudin-4 (P¼ 0.002), GRB-7
(P¼ 0.002) and c-erbB2 (P¼ 0.01) were readily apparent (Table 2
and Figure 2). Moreover, for all seven genes tested, the q-RT–PCR
data were highly correlated to the microarray data (Po0.001)
(r¼ 0.81, 0.80, 0.75, 0,69, 0.82, 0.71 and 0.65, respectively), with all
the samples (i.e., 10 USPC and five NEC) included in both the
q-RT–PCR and microarray experiments. Thus, q-RT–PCR data
suggest that most array probe sets are likely to accurately measure
the levels of the intended transcript within a complex mixture of
transcripts.
Claudin-4 expression by immunohistology on USPC and
NEC tissue blocks
To determine whether the high or low expression of the claudin-4
gene detected by microarray and q-RT–PCR assays in primary
USPC and NEC cell lines, respectively, is the result of a selection of
a subpopulation of cancer cells present in the original tumour, or
whether in vitro expansion conditions may have modified gene
Table 3 (Continued )
Probe set Gene symbol SAM P of WRS Ratio NEC/USPC Title
37512_at RODH 5.112 0.0027 11.65031202 3-Hydroxysteroid epimerase
103_at THBS4 5.114 0.0027 11.6063075 Thrombospondin 4
36156_at AQP1 6.927 0.0027 11.6016663 ‘Aquaporin 1’
39593_at FGL2 5.176 0.0027 11.38223584 Fibrinogen-like 2
33248_at HOXA11 6.555 0.0027 11.34828098 Homeo box A11
41420_at IGFBP5 4.166 0.0041 11.32365037 Insulin-like growth factor binding protein 5
35644_at HEPH 6.666 0.0027 11.26324425 Hephaestin
39646_at CACNB2 4.719 0.0027 11.25017414 ‘Calcium channel, voltage-dependent, beta 2 subunit’
35333_r_at DVS27 4.403 0.0027 11.23759398 DVS27-related protein
33182_at — 4.990 0.0027 11.20258783 Homo sapiens mRNA full-length insert cDNA clone EUROIMAGE 1630957
34303_at FLJ90798 4.909 0.0027 11.10458088 Hypothetical protein FLJ90798
33756_at AOC3 5.186 0.0027 11.09776026 ‘Amine oxidase, copper containing 3 (vascular adhesion protein 1)’
37710_at MEF2C 7.485 0.0027 11.03832245 ‘MADS box transcription enhancer factor 2, polypeptide C (myocyte enhancer
factor 2C)’
35680_r_at DPP6 3.783 0.0027 10.88151987 Dipeptidylpeptidase 6
40126_at — 4.620 0.0027 10.87424764 —
31831_at SMTN 5.712 0.0027 10.84917408 Smoothelin
234_s_at PTN 5.660 0.0041 10.803161 ‘Pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1)’
36939_at GPM6A 4.981 0.0027 10.76644676 Glycoprotein M6A
41158_at PLP1 4.879 0.0027 10.76462278 ‘Proteolipid protein 1 (Pelizaeus-Merzbacher disease, spastic paraplegia 2,
uncomplicated)’
41839_at GAS1 4.401 0.0027 10.75375673 Growth arrest-specific 1
1186_at GDF10 4.165 0.0063 10.74677086 Growth differentiation factor 10
35404_at TACR2 4.416 0.0063 10.67366905 Tachykinin receptor 2
160023_at WNT2 5.424 0.0027 10.67077677 Wingless-type MMTV integration site family member 2
34561_at MS4A2 6.380 0.0027 10.6336763 ‘Membrane-spanning 4-domains, subfamily A, member 2 (Fc fragment of IgE, high
affinity I, receptor for; beta polypeptide)’
36280_at GZMK 4.739 0.0027 10.5607572 ‘Granzyme K’
35668_at RAMP1 3.430 0.0027 10.4886967 Receptor (calcitonin) activity modifying protein 1
32521_at SFRP1 4.488 0.0027 10.43051698 Secreted frizzled-related protein 1
1975_s_at IGF1 7.381 0.0027 10.34307322 Insulin-like growth factor 1 (somatomedin C)
37671_at LAMA4 5.094 0.0027 10.34084543 ‘Laminin, alpha 4’
40013_at CLIC2 5.388 0.0027 10.2736905 Chloride intracellular channel 2
32782_r_at BPAG1 4.597 0.0027 10.2197061 ‘Bullous pemphigoid antigen 1, 230/240 kDa’
36918_at GUCY1A3 4.344 0.0027 10.18606373 ‘Guanylate cyclase 1, soluble, alpha 3’
32239_at MATN2 6.197 0.0027 10.14895891 Matrilin 2
36503_at CCL21 6.812 0.0027 10.09354903 Chemokine (C–C motif) ligand 21
38508_s_at TNXB 8.826 0.0027 10.0794719 Tenascin XB
35146_at TGFB1I1 5.562 0.0027 10.0680837 Transforming growth factor beta 1
38653_at PMP22 6.085 0.0027 10.04665889 Peripheral myelin protein 22
342_at ENPP1 5.008 0.0041 10.0434301 Ectonucleotide pyrophosphatase/phosphodiesterase
32826_at ENTPD1 6.423 0.0027 10.01186286 Ectonucleoside triphosphate diphosphohydrolase 1
40318_at DNCI1 3.348 0.0063 10.00454416 ‘Dynein, cytoplasmic, intermediate polypeptide 1’
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expression, we performed immunohistochemical analysis of
claudin-4 protein expression on formalin-fixed tumour tissue
from the uncultured primary surgical specimens from which the
USPC cell lines were derived. As shown in Table 4 and
representatively in Figure 3, both cytoplasmic and membranous
staining for claudin-4 protein expression was noted in the majority
of USPC specimens (i.e., 90% score 3þ and 2þ ). In contrast, only
low levels of membranous staining for claudin-4 protein was found
in the NEC tissue samples tested by immunohistochemistry
(Table 4, Figure 3, P¼ 0.02 USPC vs NEC by Student t-test). To
confirm and validate the immunohistochemical results in an
independent series of USPC, formalin-fixed tumour tissue blocks
from eight further surgical specimens (i.e., USPC 11–18, Table 4)
similarly obtained from patients harbouring advanced stage
disease were tested for claudin-4 expression. Again, heavy
cytoplasmic and/or membranous staining for the claudin-4
receptor was found in the striking majority of the further USPC
sample tested.
Effects of CPE on primary USPC and normal control cells
The sensitivity of primary uterine serous tumour cultures to CPE-
mediated cytolysis was tested along with an appropriate claudin-3-
and claudin-4-expressing positive control (i.e., Vero cells, obtained
from the American Type Culture Collection), and negative controls
which do not express detectable levels of either claudin-3 or
claudin-4. As shown in Figure 4, all primary USPC tested were
found highly sensitive to CPE-mediated cytolysis. The cytotoxic
effect was dose dependent and was positively correlated to the
levels of either claudin-3 or claudin-4 expression as tested by RT–
PCR in tumor samples. Importantly, although uterine serous
tumours demonstrated different sensitivities to CPE exposure, no
USPC was found viable after 24 h exposure to CPE at the
concentration of 3.3 mg ml1. In contrast, all normal controls
tested, including endometrial epithelium, fibroblasts and mono-
nuclear cells lacking claudin-3 or claudin-4, were not affected by
CPE (Figure 4).
DISCUSSION
This report represents the first communication of an investigation
involving the genome-wide examination of differences in gene
expression between primary USPC and normal endometrial cells
(NEC). In this study, we have used short-term primary USPC and
NEC cultures (to minimise the risk of a selection bias inherent in
any long-term in vitro growth) to study differential gene
expression in highly enriched populations of epithelial tumour
cells and normal cells. We found that hierarchical clustering of the
samples and gene expression levels within the samples led to the
unambiguous separation of USPC from NEC. We detected 529
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Figure 2 Quantitative RT–PCR and microarray expression analysis of
CDKN2A/p16, CDKN2A/p14ARF, claudin-3, claudin-4, GRB-7 and c-erbB2
genes differentially expressed between USPC and NEC. Quantitative RT-
PCR data were highly correlated to the microarray data (Po0.001).
Table 4 Claudin-4 staining
Patient Claudin-4 positivity
NEC 1 1+
NEC 2 1+
NEC 3 1+
NEC 4 1+
NEC 5 1+
USPC 1 3+
USPC 2 3+
USPC 3 3+
USPC 4 2+
USPC 5 3+
USPC 6 2+
USPC 7 3+
USPC 8 1+
USPC 9 3+
USPC 10 3+
USPC 11 3+
USPC 12 3+
USPC 13 1+
USPC 14 2+
USPC 15 3+
USPC 16 2+
USPC 17 3+
USPC 18 2+
Gene expression profiles of USPC
AD Santin et al
1569
British Journal of Cancer (2005) 92(8), 1561 – 1573& 2005 Cancer Research UK
G
e
n
e
ti
c
s
a
n
d
G
e
n
o
m
ic
s
genes differentially expressed between USPC and NEC, whose
average change in expression level between the two groups was at
least five-fold and which were found significant with both WRS
test and SAM analysis. The known function of some of these genes
may provide insights into the molecular pathogenesis and the
highly aggressive biologic behaviour of uterine serous tumours,
while others may prove to be useful diagnostic and therapeutic
markers against this disease.
For example, the cyclin-dependent kinase inhibitor 2A
(CDKN2A) gene was found to be the most highly differentially
expressed gene in USPC with over 101-fold upregulation relative to
NEC. Importantly, the CDKN2A gene is a putative oncosuppressor
gene encoding two unrelated proteins, both cellular growth
inhibitors, in different reading frames (Quelle et al, 1995). One is
p16, which regulates retinoblastoma protein (pRb)-dependent G1
arrest, and the second is p14ARF, which blocks MDM2-induced
p53 degradation, resulting in an increase in p53 levels and
consequent cell cycle arrest (Quelle et al, 1995). Although loss of
p53 function is considered critical for the molecular pathogenesis
of USPC (Moll et al, 1996), it is only recently that abnormality of
the Rb pathway has been suggested to define a subgroup of
aggressive endometrial carcinomas with poor prognosis (Salvesen
et al, 2000). Quantitative RT-PCR analysis of expression of both
p16 and p14ARF in our USPC series found extremely high levels of
both transcripts, suggesting that the marked overexpression of the
CDKN2A gene may be attributable to a negative feedback loop due
to the loss of function of both pRb and p53 proteins (Moll et al,
1996; Salvesen et al, 2000). Consistent with this view, an inverse
relationship between the expression of p16 and p14ARF proteins
and the presence of normal or functional Rb and p53 in human
cancer cells has been previously demonstrated (Khleif et al, 1996).
Thus, our data suggest for the first time that CDKN2A gene
overexpression may represent a consistent genetic anomaly of
USPC secondary to an autoregulatory feedback loop due to
disruption of both the p16-CDK4/cyclin D1-pRb pathway and the
p14ARF-MDM2-p53 pathway.
Among the several potential therapeutic target gene products
identified, genes encoding tight junction (TJ) proteins claudin-3
and claudin-4 were consistently found as two of the most highly
upregulated genes in USPC, with over eight- and 12-fold
upregulation, respectively, relative to NEC. To the best of our
knowledge, claudin-3 and claudin-4 overexpression has not been
previously linked to USPC. Although the exact function of claudin-
3 and claudin-4 in USPC is still unclear, these proteins have
recently been shown to represent the epithelial receptors for CPE
(Katahira et al, 1997), and to be the only family members of the
transmembrane tissue-specific claudin proteins capable of mediat-
ing CPE binding and cytolysis. As CPE may trigger a multistep
mechanism leading to efficient lysis of mammalian target cells
overexpressing claudin-3 and claudin-4 by an increase in
membrane permeability resulting in loss of osmotic equilibrium
(McClane 1996), CPE-mediated therapy might be a novel,
potentially highly effective, strategy for the treatment of USPC
refractory to chemotherapy as well as other human tumours
overexpressing claudin-3 and/or claudin-4 (Long et al, 2001; Michl
et al, 2001). Mammalian cells that do not express either claudin-3
and/or claudin-4 fail to bind CPE and are not susceptible to CPE
cytotoxicity (McClane 1996). Consistent with this view, all primary
USPC evaluated, including those found to be resistant to
chemotherapy in vivo (i.e., USPC-1 and USPC-2, data not shown),
were found highly sensitive to CPE-mediated killing in vitro. This
was in strong contrast with the lack of sensitivity of normal control
cells to CPE-mediated cytolysis. Although USPC tumours demon-
strated different sensitivity to CPE exposure, no cancer was found
viable after 24 h exposure to CPE at a concentration of 3.3 mg ml1,
a dose well tolerated by in vivo administration of CPE in murine
animal models (Wallace et al, 1999). More extensive studies will be
necessary to evaluate the potential and feasibility of CPE therapy in
vivo in human patients. Nevertheless, our results provide strong
evidence to suggest that CPE-based therapy may have great
potential in the treatment of USPC patients refractory to standard
treatment modalities. Protein expression data obtained by immuno-
histochemistry with anti-claudin-4 antibody on an independent set
Figure 3 Representative immunohistochemical staining for claudin-4 on
two paraffin-embedded USPC specimens (B–C) and one NEC specimen
(A). Normal endometrial cell 1 (upper panel) showed light membrane
staining for claudin-4, while USPC 1 and USPC 3 showed heavy cytoplasmic
and membranous staining for claudin-4 (middle and lower panel). Note the
large difference in the size of USPC cells when compared to the control
glandular epithelium of a menopausal women. Original magnification
 400.
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of USPC blocks further support the proposal that claudins may
represent therapeutic targets.
The organization of kallikreins, a gene family now consisting of
15 genes that encode for trypsin-like or chymotrypsin-like serine
proteases, has been recently elucidated (Diamandis and Yousef,
2002). Serine proteases have well-characterized roles in diverse
cellular activities, including blood coagulation, wound healing,
digestion, and immune responses, as well as tumour invasion and
metastasis (reviewed in Diamandis and Yousef, 2002). Secreted
serine proteases such as prostate-specific antigen (PSA) and
kallikrein 2 have already found important clinical application as
prostate cancer biomarkers (Diamandis and Yousef, 2002). Of
interest, kallikrein 6 (also known as zyme/protease M/neurosin)
and kallikrein-10 (NES1), two serine proteases recently shown to
be present at high levels in the circulation of a subset of ovarian
cancer patients (Diamandis et al, 2003; Luo et al, 2003), were both
highly differentially expressed genes in USPC when compared to
NEC. Kallikrein 6 and kallikrein 10 overexpression has been shown
to correlate with intrinsic resistance to adjuvant chemotherapy and
with a poor prognosis in ovarian cancer patients (Diamandis et al,
2003; Luo et al, 2003). These data are thus consistent with our
results showing high expression of kallikrein 6 and kallikrein 10 in
USPC, a variant of endometrial carcinoma characterised by an
aggressive biologic behaviour and an inborn resistance to
chemotherapy (Nicklin and Copeland, 1996). In addition, these
results further emphasise the view that kallikrein 6 and kallikrein
10 have the potential to become novel cancer markers for early
diagnosis and/or monitoring of USPC, as well as possible
immunotherapeutic targets of vaccination strategies against
recurrent/refractory serous papillary gynecologic tumours (Cannon
et al, 2002).
c-erbB2 gene was found to be one of the most highly
differentially expressed gene in USPC with over 14-fold upregula-
tion compared with NEC. Furthermore, the growth factor receptor-
bound protein 7 (GRB7), a gene tightly linked to c-erbB2 and
previously reported coamplified and coexpressed with this gene in
several cancer types (Janes et al, 1997), was also highly
differentially expressed in USPC compared to NEC. These data
confirm our recent discovery of a striking overexpression of the c-
erbB2 gene product HER2/neu on 80% of pure USPC (Santin et al,
2002). Thus, HER2/neu overexpression may represent a distinctive
molecular marker that, in addition to having the potential to
facilitate differentiation of USPC from the histologically indis-
tinguishable high-grade serious ovarian tumours (Santin et al,
2004), may also provide insights into the disproportionately poor
prognosis of USPC patients (Lukes et al, 1994; Santin et al, 2002,
2004). Previous studies have reported that HER2/neu overexpres-
sion in USPC patients may be associated with resistance to
chemotherapeutic drugs and shorter survival (Lukes et al, 1994).
However, high overexpression of the c-erbB2 gene on USPC
provides support for the notion that trastuzumab (Herceptin,
Genentech, San Francisco, CA, USA), a humanised anti-HER-2/
Neu antibody that is showing great promise for treatment of
metastatic breast cancer patients overexpressing HER-2/Neu
protein (Slamon et al, 2001), may be a novel, potentially highly
effective therapy against USPC. Consistent with this view, high
sensitivity of USPC to natural killer (NK) cell-mediated antibody-
dependent cytotoxicity triggered by anti-HER-2/Neu-specific anti-
body in vitro (Santin et al, 2002), as well as clinical responses in
vivo (Villella et al, 2003), have recently been reported with the use
of Herceptin in USPC patients.
Several other highly ranked genes have been identified in our
USPC gene expression profiling analysis, including membrane-
associated protein 17 (MAP17), galanin, urokinase plasminogen
activator receptor (UPAR), interleukin-6, forkhead box M1,
interleukin-18, dickkopf homolog 1 (DKK1), coagulation factor II
(thrombin) receptor-like 1, transforming growth factor, alpha,
interleukin 8, topoisomerase (DNA) II alpha, hyaluronan-mediated
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Figure 4 Representative dose-dependent CPE-mediated cytotoxicity of primary USPC compared to positive control Vero cells or negative controls (i.e.,
NEC, fibroblasts, and monocytes) after 24 h exposure to scalar doses of CPE. VERO, positive control cells. Uterine serous papillary carcinoma-1 to USPC-3
primary uterine serous tumors. NEC, normal endometrial cells. Fibroblasts, normal human fibroblasts. Monocytes, normal mononuclear cells.
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motility receptor (RHAMM), and secretory leukocyte protease
inhibitor (antileukoproteinase). For most of the genes found
differentially expressed in our experiments, a correlation with
USPC cancer development and progression has not been
recognised before. DKK1, for example, has been recently reported
by our group to play an important role in the development of
osteolytic lesions in multiple myeloma (Tian et al, 2003), but its
possible role in USPC pathogenesis and/or progression has not
been elucidated. For other genes such as UPAR, a glycosyl-
phosphatidylinositol-anchored glycoprotein whose role in promot-
ing tumour cell invasion and metastases has been well established
in a number of experimental studies, a correlation with high
expression in the USPC phenotype has been recently reported
(Memarzadeh et al, 2002).
A large number of downregulated (at least five-fold) genes in
USPC vs NEC, such as transforming growth factor beta receptor III,
platelet-derived growth factor receptor alpha, SEMACAP3, ras
homolog gene family member I (ARHI), and DOC1 (Table 3), have
been identified in our analysis. Some of these genes encode for
widely held tumor suppressor genes such as SEMACAP3, ARHI,
and DOC1 (Liu and Ganesan, 2002), others for proteins important
for tissue homeostasis or that have been previously implicated in
apoptosis, proliferation, adhesion, or tissue maintenance. Owing to
space limitations, we will not comment further upon the cluster of
genes that showed downregulation of the transcripts in invasive
tumours.
In conclusion, multiple USPC restricted markers have been
identified through our analysis. Most of these genes have not been
previously linked with this disease and thus represent novel
findings. The identification of HER2/neu and CPE epithelial
receptors among others as some of the most highly differentially
expressed genes in USPC when compared to NEC suggest that
therapeutic strategies targeting HER2/neu by monoclonal anti-
bodies (Villella et al, 2003) and claudin-3 and claudin-4 by local
and/or systemic administration of CPE (Long et al, 2001; Michl
et al, 2001) may represent novel potentially effective modalities for
the treatment of patients harbouring this highly aggressive and
chemotherapy-resistant variant of endometrial cancer. The future
design and implementation of clinical trials at this regard will
ultimately determine the validity of these approaches.
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